Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| SMPH/OB-GYN/GYN ONCOLOGY | Other Identifier | UW Madison | |
| Protocol Version 7/23/25 | Other Identifier | UW Madison | |
| UW25061 | Other Identifier | OnCore ID |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.
Participants undergoing neoadjuvant chemotherapy for newly diagnosed, advanced epithelial ovarian cancer will be assessed for patient reported outcomes (including subjective cognitive impairment) and objective cognitive function at baseline, following three cycles of neoadjuvant chemotherapy, at the completion of adjuvant chemotherapy or transition to alternate treatment regimen for patients who progress through primary treatment, and six months following treatment completion. Patient reported outcomes will be assessed using the FACT-O and subjective cognitive impairment will be assessed using the FACT-Cog surveys.
The NCCN distress thermometer is used to screen for distress levels routinely in the gynecologic oncology clinic. For those who complete this screening as part of their clinical care, those results will also be used as a quality of life measure. The cognitive domains of learning and memory, processing speed, and executive function will be assessed using the Rey Verbal Learning Test, Trail Making Test, and the Controlled Oral Word Association of the Multilingual Aphasia Examination, as recommended by the International Cognition and Cancer Task force for studies of cognition in cancer patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Receiving Neoadjuvant Chemotherapy for Ovarian Cancer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient Reported Outcomes Assessment | Other | Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess patient reported outcomes. |
| Measure | Description | Time Frame |
|---|---|---|
| The Mini Mental State Exam (MMSE) | The MMSE is a common overall test of cognition used in research and clinical settings. It is an 11 item test that assesses five domains of cognition: orientation, registration, attention, recall and language. This measure takes around 5-10 minutes to complete and is scored out of 30 with scores of 18-23 representing mild cognitive impairment and scores of 17 or less representing severe cognitive impairment. | baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) |
| Measure | Description | Time Frame |
|---|---|---|
| Controlled Oral Word Association Test (COWAT) | Participant is asked to list as many words (other than people's names or places) beginning with a specific letter as they can in one minute. Number of unique words that qualify are counted. | baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants scheduled to receive neoadjuvant chemotherapy for treatment of ovarian cancer.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Supportive Oncology | Contact | (608)263-6002 | supportiveoncology@uwcarbone.wisc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Lisa Barroilhet, MD | UW Carbone Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UW Carbone Cancer Center | Recruiting | Madison | Wisconsin | 53792 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
optional blood draw for research purposes
|
| Cognitive and General Health Assessments | Other |
|
|
| Trail Making Test (TMT) Parts A and B | The TMT is a test of complex attention. Part A asks participants to connect circles on a page containing the numbers 1-25 in ascending order. Part B asks participants to connect circles containing the numbers 1-13 and the letters A-L in alternating ascending order (eg: 1, A, 2, B, etc). These tests are timed and a participant's score is the amount of time it takes to complete the entire task for each part; errors do not incur a score penalty but contribute to the overall time to complete the task. This takes approximately 5-10 minutes to complete | baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) |
| Patient Health Questionnaire-2 (PHQ-2) | The PHQ2 is a two item screening test that asks about the frequency of depressed mood and anhedonia over the past two weeks. Subjects whose answers receive a score of three or greater (on a scale of 0-6) are considered to be at risk for depression and should undergo further evaluation. This screening test takes around one minute to administer. | baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) |
| Functional Assessment of Cancer Therapy - Ovarian (FACT-O) | The FACT-O is a validated and commonly used quality of life assessment utilized in many clinical research studies that assess 39 items/symptoms common amongst cancer patients generally with items included that are specifically common amongst ovarian cancer patients, including questions related to gastrointestinal symptoms and sexual health. Total scores range from 0 - 156 with higher scores indicative of better quality of life. | baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) |
| Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) | The FACT-Cog is a patient reported outcomes measure assessing 37 cognitively-related symptoms, as well as their perceived impact on quality of life from the past 7 days. Scoring is from 0-4 in each of the following domains: perceived cognitive impairments, comments from others, perceived cognitive abilities, impact on quality of life. Total scores range from 0 -148 with higher scores indicating better perceived cognitive functioning. | baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) |
| Rey Auditory Verbal Learning Test (RAVLT) | The RAVLT is a test of immediate memory and verbal learning where participants are given three trials to recall as many words as possible from a 15-item list. Participants are asked to repeat this list one additional time after a 5-25 minute delay. This takes around 4 minutes to complete. Number of correct words from the list of 15 are reported for each trial. | baseline, after 3 cycles of neoadjuvant chemotherapy (up to 2 months), after completion of adjuvant therapy (up to 4 months), and 6 months following treatment (up to 10 months on study) |
| D000291 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |